ZHB 015
Alternative Names: ZHB-015; ZHB-C003Latest Information Update: 28 Jul 2025
At a glance
- Originator Jiangsu ZonHon Biopharma Institute
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 Jul 2025 Jiangsu ZonHon Biopharma Institute has patents pending for ZHB 015 in China, USA and European Union (Jiangsu ZonHon Biopharma Institute pipeline, July 2025)
- 23 Jul 2025 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (Parenteral) before July 2025 (Jiangsu ZhonHon Biopharma Institute pipeline, July 2025)
- 25 Apr 2025 Preclinical trials in Solid tumours in China (Parenteral) before April 2025